RealRate Inc., 2040 Martin Ave., Santa Clara, CA 95050

RealRate

July 10, 2026

To the CEO
Abeona Therapeutics INC
6555 CARNEGIE AVE, 4TH FLOOR
CLEVELAND, OH 44103
USA

Abeona Therapeutics INC TOP Rated in the US Pharmaceutical Ranking

Dear Sir or Madam,

at RealRate we have just published the 2026 US Pharmaceutical ranking. I am happy to inform you that Abeona Therapeutics INC has been TOP Rated at rank 18 out of 178.

Overall, 178 US companies were analyzed with respect to their financial strength. The complete rating is published at https://www.realrate.ai/rankings. Your individual rating report, showing your strengths compared to your competitors is attached.

RealRate is an international rating agency based in Santa Clara and Berlin. We use artificial intelligence to create fair and explainable company ratings. Customers highly appreciate the RealRate rating seal: only the strongest companies are able to offer highly attractive and innovative products with top customer services. Billion dollar companies rely on our rating and build trust with their customers.

You too can acquire the RealRate seal and advertise with it. We only reach out to the top-rated companies, like yours and only those may subscribe for our seal. Save a lot of money and effort compared to traditional rating agencies: get a RealRate seal for just $9,900. Simply sign the attached order form and send it back via email.

Please feel free to book a short video call with me: https://calendly.com/holger-bartel

Sincerely,

Dr. Holger Bartel, CEO

RealRate Seal Subscription

RealRate Inc.
2040 Martin Ave., Santa Clara, California 95050, USA
Via email to: holger.bartel@realrate.ai

We subscribe to the Pharmaceutical RealRate rating for Abeona Therapeutics INC. The subscription comprises the annual rating update. The invoice will be sent annually, provided that a TOP rating is achieved again. The subscription can be cancelled by written letter, effective for the following year.

RealRate provides the rating seal as a scalable vector graphic. It can be used without any restrictions by Abeona Therapeutics INC (Customer) for all promotional purposes, i.e. in product brochures, presentations, websites and broadcasting.

Item	**2026 US Pharmaceutical RealRate rating seal for Abeona Therapeutics INC**
Amount	**USD 9,900**
Order no.	2026-0000318306

Amounts payable by Customer are exclusive of taxes. Customer is responsible for all his taxes and will pay such amounts invoiced by RealRate.

Billing address

Company name		Full name	
Street address		Department	
City		Phone number	
State / provice		Email address	
ZIP code			
Country			

Shipping address
The electronic RealRate rating seal and the invoice will be sent to

Delivery email	

Abeona Therapeutics INC

Date, location, name

PHARMACEUTICAL 2026

Abeona Therapeutics INC
Rank 18 of 178



Abeona Therapeutics INC
Rank 18 of 178

The relative strengths and weaknesses of Abeona Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Abeona Therapeutics INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 85% points.The greatest weakness of Abeona Therapeutics INC is the variable Other Revenues, reducing the Economic Capital Ratio by 21% points.

The company's Economic Capital Ratio, given in the ranking table, is 368%, being 139% points above the market average of 229%.

Input Variable	Value in 1000 USD
Assets, Current	204,906
Cost of Goods Sold	1,532
Intangible Assets	0
Liabilities, Current	29,570
Liabilities, Non-Current	11,882
Other Assets	4,743
Other Compr. Net Income	130
Other Expenses	-406
Other Liabilities	18,902
Other Net Income	158,332
Other Revenues	5,820
Property and Equipment	9,921
Research and Development	26,812
Selling, General and Administrative Expense	65,031

Output Variable	Value in 1000 USD
Assets	219,570
Liabilities	60,354
Expenses	92,969
Revenues	5,820
Stockholders Equity	159,216
Net Income	71,183
Comprehensive Net Income	71,248
BaseVar	268,588
ECR before LimitedLiability	299%
Economic Capital Ratio	368%